The Biotech Beat: 4/1 - 4/7/24
by Joey Bose
🌟Upshot
💉 Setback in the Alzheimer's Battle: Eisai and Biogen's Subcutaneous Leqembi Delayed by FDA Inquiry
💰 Roivant's Bold Move: $1.5 Billion Buyback and Promising Brepocitinib Data
🧬 Gene Editing Hurdle: Verve Therapeutics Pauses VERVE-101 Study Amid Safety Concerns
💉 Moderna's mRNA Odyssey: A Glimpse of Hope in Rare Disease Therapy Amid Challenges
🏥 Amylyx's Ethical Exit: Relyvrio Withdrawn from ALS Market After Failed Trial
📉 Contineum Therapeutics Adjusts IPO Ambitions: A Cautious Step in Biotech's Public Debut
🔬 Genmab's Bold Move: $1.8 Billion Acquisition of ProfoundBio to Challenge AbbVie in Cancer Therapy
❤️ J&J's Heartfelt Investment: $13.1 Billion Acquisition of Shockwave Medical Bolsters Cardiovascular Portfolio
🔍 WuXi AppTec's IP Transfer Controversy: A Tense Intersection of Biotech and Geopolitics
💊 CMS Seeks Further Discussions with Pharma Companies on IRA Price Negotiations
🔒 US Crackdown on WuXi Companies Raises Concerns of Clinical Trial Delays and Drug Shortages
💊 Biden Pushes for Aggressive Expansion of Drug Price Negotiations Under the IRA
🔬 Research, Development & Drug Approvals 💊
💉 Setback in the Alzheimer's Battle: Eisai and Biogen's Subcutaneous Leqembi Delayed by FDA Inquiry
The Facts
Eisai and Biogen's plan to market a subcutaneous version of their Alzheimer's drug Leqembi is facing a delay due to the FDA's request for more information on its immunogenicity. The company had aimed to start a rolling review last month but now awaits a decision on a fast track designation for the subcutaneous drug, expected within 60 days. The original intravenous form of Leqembi was approved in January 2023. Analysts express disappointment and concern over the delay, highlighting its impact on investor sentiment and adding uncertainty to Eisai's outlook.
Our Opinion
The delay in the approval process for the subcutaneous form of Leqembi underscores the intricate challenges faced by biotech companies in bringing innovative therapies to market. In the context of Alzheimer's, a disease with limited treatment options, any setback can be disheartening. However, this situation also emphasizes the importance of rigorous regulatory oversight to ensure the safety and efficacy of new drug formulations. For the biotech industry, navigating these regulatory hurdles is crucial for maintaining investor confidence and advancing the development of breakthrough treatments.
Your Turn
Considering the increasing prevalence of Alzheimer's, how might delays in drug approvals affect the overall economic burden of the disease on healthcare systems and families?
🧬 Gene Editing Hurdle: Verve Therapeutics Pauses VERVE-101 Study Amid Safety Concerns
The Facts
Verve Therapeutics has halted enrollment in a Phase 1 trial of its lead gene editing medicine, VERVE-101, due to safety concerns. One of six patients treated with a 0.45-mg/kg dose experienced significant increases in liver enzymes and a case of low blood platelets, leading to hospitalization. As a result, Verve is pivoting to a follow-up asset, VERVE-102, which utilizes different lipid nanoparticle technology for delivery. The first patient for the VERVE-102 trial is expected to be dosed in the second quarter. Despite the setback, VERVE-101 showed promising results, with a 46% average drop in low-density lipoprotein cholesterol levels among the first five patients.
Our Opinion
The temporary halt of the VERVE-101 trial underscores the delicate balance between innovation and safety in the development of gene editing therapies. While the technology holds immense potential for treating conditions like serious high cholesterol, it also poses unique challenges, particularly regarding delivery mechanisms and unintended effects. Verve Therapeutics' swift response and pivot to VERVE-102 demonstrate the company's commitment to addressing these challenges while advancing the field of gene editing. For the biotech industry, this situation highlights the importance of rigorous clinical testing and adaptive strategies in bringing groundbreaking treatments to market.
Your Turn
How does the use of different lipid nanoparticle technologies impact the safety and efficacy of gene editing therapies, and what lessons can be drawn from Verve Therapeutics' experience with VERVE-101 and VERVE-102?
💉 Moderna's mRNA Odyssey: A Glimpse of Hope in Rare Disease Therapy Amid Challenges
The Facts
Moderna, primarily known for its Covid-19 vaccine, is making strides in rare disease therapy with its mRNA-based treatment, mRNA-3927, for propionic acidemia. Interim results from an early study showed some patients, mostly children, experienced a reduction in life-threatening metabolic emergencies. Despite side effects like fever and vomiting, most patients wanted to continue the drug post-trial. The therapy is given intravenously every two weeks, and Moderna plans to start a pivotal trial later this year. The study included 16 patients aged 1 to 26, with nearly all reporting side effects. The therapy aims to address the lack of functional enzymes required to metabolize fats and proteins, a key issue in propionic acidemia.
Our Opinion
Moderna's venture into mRNA-based therapies for rare diseases like propionic acidemia represents a significant leap forward in biotechnology. The interim results from the study of mRNA-3927 not only validate the potential of mRNA as a therapeutic tool but also highlight the complexities and challenges in developing such treatments. The need for frequent dosing and the occurrence of side effects underscore the importance of ongoing research to enhance the stability and delivery of mRNA therapies. For the biotech industry, this marks a pivotal moment in exploring the versatility of mRNA beyond vaccines, opening new avenues for treating genetic disorders with unmet medical needs.
Your Turn
Considering the challenges associated with frequent dosing and side effects in mRNA therapies, what innovations in drug delivery systems could improve patient compliance and overall treatment efficacy?
🏥 Amylyx's Ethical Exit: Relyvrio Withdrawn from ALS Market After Failed Trial
The Facts
Amylyx Pharmaceuticals is withdrawing its ALS drug Relyvrio from the U.S. and Canadian markets following a failed Phase 3 study. The drug, approved in 2022 based on modest data, failed to outperform a placebo in a recent trial involving 664 people. Despite the setback, Amylyx has been praised for its ethical decision to remove the drug, aligning with its co-CEOs' promise to do so if further testing did not show a benefit. The company will offer Relyvrio free of charge to patients currently taking it and plans to focus on two clinical-stage drugs for other conditions. Amylyx also announced a 70% staff reduction in response to the withdrawal.
Our Opinion
Amylyx Pharmaceuticals' decision to withdraw Relyvrio from the market is a commendable example of ethical conduct in the biopharmaceutical industry. By prioritizing patient safety and scientific integrity over profits, the company sets a high standard for transparency and accountability. This move is particularly significant in the context of ALS, a disease with limited treatment options, highlighting the importance of rigorous clinical testing and honest communication with patients and stakeholders. As the industry continues to navigate the complexities of drug development and approval, Amylyx's approach serves as a reminder of the ethical responsibilities that come with the pursuit of medical innovation.
Your Turn
In light of the high pricing of Relyvrio despite its uncertain efficacy, how should biopharmaceutical companies balance the costs of drug development with ethical pricing strategies, especially for treatments targeting rare diseases?
💰 Investment, M&A, and IPOs 📈
💰 Roivant's Bold Move: $1.5 Billion Buyback and Promising Brepocitinib Data
The Facts
Roivant announced a $1.5 billion share repurchase program and revealed promising Phase 2 trial data for brepocitinib, a JAK1 and TYK2 inhibitor. The drug showed potential in treating non-infectious uveitis, with only 29% of patients experiencing treatment failure at a 45 mg dose. Roivant's stock surged 5% in premarket trading following the news. The company is also planning a Phase 3 study for brepocitinib and is in discussions with the FDA. Additionally, Roivant aims to buy back shares from Sumitomo Pharma and other pre-public owners, leveraging its substantial cash reserves from a previous deal with Roche.
Our Opinion
Roivant's strategic decisions highlight a proactive approach to capital management and drug development in the biotech industry. The share repurchase program demonstrates confidence in the company's value and future prospects, while the promising data for brepocitinib in treating non-infectious uveitis showcases Roivant's commitment to addressing unmet medical needs. These moves not only enhance shareholder value but also underline the importance of innovative therapies in improving patient outcomes and advancing the biotech sector.
Your Turn
In what ways might Roivant's focus on orphan and rare diseases, as demonstrated by the development of brepocitinib for non-infectious uveitis, influence the allocation of research and development resources in the biotech industry?
📉 Contineum Therapeutics Adjusts IPO Ambitions: A Cautious Step in Biotech's Public Debut
The Facts
Contineum Therapeutics, a biotech company partnered with Johnson & Johnson, has revised its IPO expectations, pricing its shares at $16 each, the lower end of its initial range, and reducing the number of shares to 6.87 million. This adjustment results in gross proceeds of $110 million, with a potential increase of $16.5 million if underwriters exercise their option. The company plans to use the funds for Phase 1b and 2 trials of its lead drug candidate, PIPE-791, for idiopathic pulmonary fibrosis and progressive multiple sclerosis, as well as a Phase 2 trial of PIPE-307 for relapsing-remitting MS as part of its agreement with J&J.
Our Opinion
Contineum Therapeutics' decision to lower its IPO expectations reflects a cautious approach in a fluctuating biotech market. While the reduced valuation may seem disappointing, it is a pragmatic strategy to ensure a successful public debut and secure necessary funding for critical clinical trials. This move highlights the challenges biotech companies face in balancing market expectations with the realities of drug development. For the industry, Contineum's IPO serves as a reminder of the importance of adaptability and financial prudence in advancing innovative therapies.
Your Turn
How does the adjustment of IPO expectations by Contineum Therapeutics impact investor confidence in the biotech sector, particularly in the context of recent market volatility?
🔬 Genmab's Bold Move: $1.8 Billion Acquisition of ProfoundBio to Challenge AbbVie in Cancer Therapy
The Facts
Genmab, a Danish biotech company, is investing $1.8 billion to acquire ProfoundBio and gain control of a mid-phase antibody-drug conjugate (ADC), rinatabart sesutecan (Rina-S), that could compete with AbbVie's Elahere in treating ovarian cancer and other solid tumors. Rina-S is designed to deliver a topoisomerase-1 inhibitor to cells expressing the folate receptor alpha (FRα), a target overexpressed in several cancers. Genmab sees Rina-S as a potential best-in-class asset and plans to use it to expand its presence in the cancer therapy market. The acquisition also includes other ADC candidates targeting CD70, PTK7, EGFR, and cMET, further enhancing Genmab's pipeline.
Our Opinion
Genmab's strategic acquisition of ProfoundBio represents a significant shift in its approach, moving from acquiring tools and components to acquiring drug candidates directly. This bold move not only demonstrates Genmab's confidence in Rina-S as a potential competitor to AbbVie's Elahere but also highlights the growing importance of ADCs in the cancer therapy landscape. By leveraging its expertise in antibody development and ProfoundBio's innovative platforms, Genmab is positioning itself as a major player in the oncology field, with the potential to offer new treatment options for patients with FRα-expressing tumors.
Your Turn
Considering the competitive nature of the oncology market, what are the potential challenges and opportunities for Genmab in establishing Rina-S as a best-in-class therapy for FRα-expressing tumors?
❤️ J&J's Heartfelt Investment: $13.1 Billion Acquisition of Shockwave Medical Bolsters Cardiovascular Portfolio
The Facts
Johnson & Johnson has announced a $13.1 billion acquisition of Shockwave Medical, a move that significantly expands its cardiovascular interventions portfolio. Shockwave Medical, known for its intravascular lithotripsy (IVL) technology, recorded a 49% increase in revenue in 2023, reaching $730.2 million. The technology is used to treat coronary and peripheral artery disease by cracking calcium deposits and improving blood flow. J&J's acquisition aligns with its recent focus on medical technology companies and its ongoing efforts in cardiovascular therapeutics, including the development of milvexian and the approval of Opsynvi for pulmonary arterial hypertension.
Our Opinion
Johnson & Johnson's strategic acquisition of Shockwave Medical underscores the healthcare giant's commitment to innovation in cardiovascular care. By integrating Shockwave's advanced IVL technology into its portfolio, J&J is poised to address the growing demand for minimally invasive treatments for artery diseases. This acquisition not only strengthens J&J's position in the medical technology market but also highlights the importance of continued investment in technologies that can improve patient outcomes. As J&J continues to expand its cardiovascular offerings, patients worldwide stand to benefit from more effective and less invasive treatment options.
Your Turn
How does Johnson & Johnson's acquisition of Shockwave Medical reflect the broader trend of consolidation in the medical technology industry?
⚖️ Politics & Policy 🏛️
🔍 WuXi AppTec's IP Transfer Controversy: A Tense Intersection of Biotech and Geopolitics
The Facts
WuXi AppTec, a prominent Chinese contract research organization (CRO), is reportedly under scrutiny after American intelligence officials informed Congress about the unauthorized transfer of a US client's intellectual property to Chinese authorities. This briefing has raised concerns about the conduct of WuXi AppTec and other Chinese companies, leading to the advancement of the BIOSECURE Act in the Senate, which aims to restrict the operations of WuXi and other Chinese healthcare firms in the US. The allegations have sparked a debate about the potential impact of disentangling the biotech and pharma industries from WuXi AppTec, which could lead to delays and shortages affecting a wide range of companies.
Our Opinion
The allegations against WuXi AppTec highlight the delicate balance between leveraging global resources for scientific advancement and protecting national security interests. As the biotech and pharma industries increasingly rely on international collaborations, it is crucial to establish transparent and secure channels for intellectual property exchange. The proposed BIOSECURE Act underscores the need for stringent regulations to safeguard sensitive information while promoting innovation. This situation serves as a reminder of the importance of due diligence and robust cybersecurity measures in the rapidly evolving landscape of biotechnology.
Your Turn
What are the potential implications of restricting the operations of Chinese healthcare firms like WuXi AppTec in the US, both for the companies involved and the overall biotech ecosystem?
💊 CMS Seeks Further Discussions with Pharma Companies on IRA Price Negotiations
The Facts
The Centers for Medicare & Medicaid Services (CMS) is requesting additional discussions with pharmaceutical companies participating in the Inflation Reduction Act (IRA) price negotiations. According to the agency, responses to counteroffers proposed by manufacturers have been sent, and up to three negotiation meetings will be held before the deadline on August 1. Despite legal challenges by pharma companies arguing that the legislation will harm innovation, CMS plans to publish explanations for negotiated prices by March 1, 2025, with discounts taking effect in January 2026. The Center for American Progress predicts significant Medicare price reductions for various drugs, including NovoLog FlexPen and Imbruvica.
Our Opinion
The CMS's move to engage in further discussions with pharmaceutical companies underscores the complexity and importance of the IRA price negotiations. The potential for significant cost savings for Medicare beneficiaries is a promising aspect of the IRA, but it is crucial to strike a balance between reducing drug prices and ensuring continued innovation in the pharmaceutical industry. The ongoing legal challenges reflect the contentious nature of this issue, and the outcomes of these negotiations and legal battles will have far-reaching implications for healthcare policy, drug pricing, and patient access to medications.
Your Turn
What are the potential impacts of the IRA price negotiations on pharmaceutical innovation, and how can policymakers balance cost containment with encouraging drug development?
🔒 US Crackdown on WuXi Companies Raises Concerns of Clinical Trial Delays and Drug Shortages
The Facts
A growing number of pharmaceutical companies, including Merck, Cabaletta Bio, and Kyverna Therapeutics, are warning of potential clinical trial delays and drug shortages due to potential US government actions against WuXi companies. Nearly three dozen companies have disclosed their reliance on WuXi for services such as cell manufacturing and testing. The concerns stem from ongoing US measures targeting WuXi, including sanctions and the Biosecure Act, amid allegations of unauthorized intellectual property transfer to Chinese authorities. Companies are now evaluating the risks and exploring alternatives, with some, like Sound Pharmaceuticals, maintaining their relationship with WuXi despite the scrutiny.
Our Opinion
The potential US crackdown on WuXi companies highlights the complex interdependencies within the global pharmaceutical supply chain. While ensuring national security is paramount, it's crucial to consider the potential repercussions on drug development and patient access to therapies. This situation underscores the need for a balanced approach that safeguards intellectual property and maintains the integrity of the pharmaceutical industry while avoiding disruptions to critical research and development activities.
Your Turn
What strategies can pharmaceutical companies adopt to mitigate the risks associated with reliance on single suppliers like WuXi, particularly in the context of cell manufacturing and testing for advanced therapies?
💊"We Beat Pharma..." Biden Pushes for Aggressive Expansion of Drug Price Negotiations Under the IRA
The Facts
President Joe Biden has renewed his proposal to expand drug price negotiations under the Inflation Reduction Act (IRA), aiming to be more aggressive in lowering the costs of prescription drugs. He advocated for negotiating prices for at least 50 drugs annually and capping out-of-pocket expenses for all Americans. Despite ongoing negotiations for the first 10 products on CMS' list, with discounts set to take effect in 2026, the pharma industry has criticized these efforts. Biden's call for expansion comes as CMS continues discussions with drugmakers, following responses to all counteroffers proposed by the companies.
Our Opinion
President Biden's proposal to expand drug price negotiations signifies a bold step towards making healthcare more affordable for Americans. By targeting a broader range of drugs and capping out-of-pocket costs, the administration aims to alleviate the financial burden on patients and taxpayers. However, the pharma industry's resistance and ongoing legal battles underscore the complexity of implementing such reforms. As negotiations progress, it will be crucial to find a balance that ensures both affordability for consumers and sustainability for drug innovation.
Your Turn
How would expanding drug price negotiations to include more drugs impact the value proposition of drug development in the United States, and what are the downstream consequences of shifting this risk/reward profile?
If you enjoyed this article, be sure to subscribe and follow Joey Bose!
Disclaimer: The contents of this article are not to be construed with investment advice. The information presented in this article is a compilation of current events, technical analyses, corporate press releases, and the author's personal viewpoints about the biotechnology industry. While efforts have been made to provide accurate and timely information, there may be inadvertent errors, omissions, or inaccuracies. Therefore, investment decisions should not be made solely based on the content of this article. The article may contain statements that are forward-looking in nature, encompassing predictions and future expectations that are subject to inherent risks and uncertainties; as such, actual outcomes may significantly deviate from those expressed or implied herein. This article serves purely as an informational and entertainment resource, and should not be construed as an endorsement to purchase or sell any financial securities. Prior to engaging in any investment activities, it is imperative that you conduct comprehensive due diligence and consult with a qualified financial advisor.